Page History
Anchor maincontent maincontent
Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
X | ||
X | ||
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
...
Item | Who | Talking Points |
---|---|---|
Steering Committee Meeting Updates | Unknown User (parchmentr) |
|
ICDC Next Phase |
| |
DGAB Updates |
| |
Data Use Guidelines |
| |
User Research for ICDC by the Office of Communications and Public Liaison (OCPL) | Kuffel, Gina (NIH/NCI) [C] |
|
ICDC Site Updates |
|
Minutes (Not Verbatim)
TH- If you find differences, this can be compared with human data to compare the prevalence.
EK- Potential extra credit question
TH- Should include some human aspect.
EK- Scope of this exercise is limited to ICDC portal
TH- Emphasize the downstream possibilities.
DK- There is a group at Purdue utilizing brain cancer data in ICDC to ask new questions, one thing they have done is to acquire true normals, what is in ICDC now are adjacent normals. These new controls provide new insights. They are looking at astros vs. oligos. It might help to have the normals available.
TH- Range of expertise is needed to form a committee for the future phase of ICDC. We have to know how can we make sense of the data and develop new hypothesis. Very few people have volunteered.
CS- Dan Regan, Nikki, and Cheryl volunteered.
AL- Happy to volunteer as well.
TH- Will organize something early February for a formal brainstorming session. This will be used to inform the case proposed to Ned Sharpless. I would like to get Warren Kibbe on this panel. As head of the DGAB it would be appropriate.
DK- Happy to volunteer as well.
TH- Thinking through some ideas myself. Outside the box ideas are welcome as well.
RP- From precision medicine, what is the dog model for the human disease I am studying, what are the considerations for differences in dosing ideas
TH- Come up with a statement for a precision medicine use case
AL- Harmonizing theme is we need data that helps to inform the molecular landscape of various cancers with an emphasis on targeted drug development. On Osteo we have discovered a gene signature that clusters and this holds true in humans as well. Opens up ideas of drug therapies.
RP- Body of knowledge available if there is translational research is being conducted.
TH- Longitudinal studies would be preferential.
RP- Clinical agents that have performed well in canine that have never been tried in human.
TH- Is it useful for PD group to hear about ICDC?
RP- I think so, we are in the process of coming up with some use cases for possible data submission, I think people don't ask questions because it is not part of the their daily work life at this moment. Use case: where is LINE3 expressed in the dog
AL- Many people have FFPE samples of canine cancers available, trouble is validated tissue expression, don't have good IHC antibodies.
TH- Immunology field in canines is way behind that of human.
Previous ICDC Use Cases from Steering Committee
...
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
The Future of ICDC Committee
- Toby Hecht
- Connie Sommers
- Amy LeBlanc
- Debbie Knapp
- John Otridge
- Ralph Parchment
- Erika Kim
- Dan R
Previous Meeting Minutes (Not Verbatim)
...
TH- Reference standards are prolific at this point. There is a new canine reference German Shepherd 1.0 named Mischka.
Action items
- Kim, Erika (NIH/NCI) [E] to send out Data Use Guidelines to Office of Data Sharing
- Kuffel, Gina (NIH/NCI) [C] to send official list of Future Committee to Toby